Evaluating extended-release injectable buprenorphine in a Canadian setting

Canada is in the midst of an opioid epidemic. Although oral opioid agonist therapies (OAT) are effective for the treatment of opioid use disorder (OUD), a number of barriers pose a significant challenge to treatment initiation and retention. In 2018, Health Canada approved a new medication for OUD, a once-monthly injection, which may be able to address challenges related to medication adherence. The current project aims to support a larger observational study that assess the feasibility, efficacy, and safety of this new treatment option. The current project will ensure greater transparency in the research process and generate awareness of the study. Overall, this will support knowledge generation that will inform clinical practice and may contribute to improved health outcomes for individuals with OUD, a population of emphasis at Providence Health Care (the partner organization).

Faculty Supervisor:

M. Eugenia Socias;Nadia Fairbairn

Student:

Partner:

Providence Health Care

Discipline:

Life Sciences

Sector:

Health and Related Sciences & Technology; Professional, scientific and technical services

University:

The University of British Columbia

Program: